LU91205I2 - Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) - Google Patents

Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Info

Publication number
LU91205I2
LU91205I2 LU91205C LU91205C LU91205I2 LU 91205 I2 LU91205 I2 LU 91205I2 LU 91205 C LU91205 C LU 91205C LU 91205 C LU91205 C LU 91205C LU 91205 I2 LU91205 I2 LU 91205I2
Authority
LU
Luxembourg
Prior art keywords
alvesco
ciclesonide
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU91205C
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of LU91205I2 publication Critical patent/LU91205I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91205C 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco) LU91205I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57894290A 1990-09-07 1990-09-07

Publications (1)

Publication Number Publication Date
LU91205I2 true LU91205I2 (fr) 2006-05-30

Family

ID=24314964

Family Applications (2)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires
LU91205C LU91205I2 (fr) 1990-09-07 2005-11-09 Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU88001A LU88001A1 (fr) 1990-09-07 1991-09-04 Nouveaux esters pregna-1,4-diene-3,20-dione-16-17-acetal-21,procede pour leur preparation,et methodes pour le traitement des conditions inflammatoires

Country Status (19)

Country Link
US (1) US5482934A (fr)
JP (1) JP3292928B2 (fr)
KR (1) KR100193085B1 (fr)
AT (1) AT402930B (fr)
AU (1) AU649472B2 (fr)
BE (1) BE1005876A5 (fr)
BR (1) BR1100860A (fr)
CA (1) CA2050812C (fr)
CH (1) CH683343A5 (fr)
DE (2) DE4129535C2 (fr)
ES (1) ES2034893B1 (fr)
FR (1) FR2666585B1 (fr)
GB (1) GB2247680B (fr)
GR (1) GR1001529B (fr)
HK (1) HK1005881A1 (fr)
IT (1) IT1251376B (fr)
LU (2) LU88001A1 (fr)
NL (2) NL194917C (fr)
PT (1) PT98897B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
UA26230A (uk) * 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
ES2124884T3 (es) * 1993-04-02 1999-02-16 Byk Gulden Lomberg Chem Fab Nuevos derivados de prednisolona.
EP0749438B1 (fr) * 1994-03-09 2000-12-13 Byk Gulden Lomberg Chemische Fabrik GmbH Nouveaux composes silyle et leur utilisation
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
SE9604751D0 (sv) * 1996-12-20 1996-12-20 Astra Ab New therapy
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
DE10055820C1 (de) * 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
CN1264855C (zh) * 2000-11-10 2006-07-19 奥坦纳医药公司 通过转缩酮化生产16,17－[（环己基亚甲基)双(氧基)]－11,21－二羟－孕－1,4－二烯－3,20－二酮或其21－异丁酸酯的方法
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP1490090A4 (fr) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DK1545548T3 (da) 2002-08-30 2010-09-27 Nycomed Gmbh Anvendelsen af kombinationen af ciclesonid og antihistaminer til behandingen af allergisk rhinitis
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
DK1572217T3 (da) 2002-12-12 2008-12-15 Nycomed Gmbh Kombinationsmedikament af R,R-formoterol og ciclesonid
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
CN100404545C (zh) * 2003-03-27 2008-07-23 尼科梅德有限责任公司 具有规定粒径的结晶环缩松的制备方法
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
JP2006527237A (ja) 2003-06-13 2006-11-30 アルタナ　ファルマ　アクチエンゲゼルシャフト ホルモテロールと及びシクレソニドの組合せ物
GB0315889D0 (en) * 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
WO2005021515A2 (fr) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase de type iv
ES2350396T3 (es) * 2003-09-15 2011-01-21 Nycomed Gmbh Uso de ciclesonida para el tratamiento de enfermedades intestinales inflamatorias.
DK1670482T4 (da) * 2003-09-16 2022-08-22 Covis Pharma B V Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US20070134165A1 (en) * 2004-04-20 2007-06-14 Altana Pharma Ag Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient
CN100338089C (zh) * 2004-08-12 2007-09-19 重庆医药工业研究院有限责任公司 一种哮喘病治疗药物环索奈德的新的制备方法
JP2008512428A (ja) * 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
CN100345864C (zh) * 2004-10-29 2007-10-31 天津药业研究院有限公司 一种治疗呼吸道疾病的甾体药物的制备方法及其中间体
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
EP1893220A4 (fr) * 2005-06-14 2011-06-15 Gilead Sciences Inc Phenylphosphates substitues utilises en tant que promedicaments mutuels constitues de steroides et de beta-agonistes pour le traitement d'inflammation pulmonaire et de bronchoconstriction
CN1325508C (zh) * 2005-06-21 2007-07-11 浙江仙琚制药股份有限公司 一锅法制备泼尼松龙衍生物
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
CN101300265A (zh) * 2005-09-02 2008-11-05 尼科克斯公司 糖皮质激素硝酰氧基衍生物
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
CA2637815A1 (fr) * 2006-02-08 2007-08-16 Sicor Inc. Formes cristallines de ciclesonide
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2008015696A2 (fr) * 2006-05-23 2008-02-07 Cadila Healthcare Limited Procédé pour préparer le ciclésonide
AU2007275931B2 (en) 2006-07-19 2011-06-16 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
MX2009001963A (es) 2006-08-22 2009-03-30 Ranbaxy Lab Ltd Inhibidores de metaloproteinasa de matriz.
WO2008062450A2 (fr) * 2006-09-18 2008-05-29 Cadila Healthcare Limited Polymorphes cristallins de ciclésonide
AU2007298770B2 (en) 2006-09-19 2013-01-31 Cipla Limited Processes for the preparation of ciclesonide and its crystal form
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
CA2664247A1 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase type iv
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
EP2121137B1 (fr) 2006-12-19 2012-04-25 AstraZeneca AB Dérivés quinuclidinol utilisés en tant qu'antagonistes du récepteur muscarinique
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
WO2008111009A1 (fr) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérases
EP2124944B1 (fr) * 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérase
EP2022796A1 (fr) * 2007-08-07 2009-02-11 Nycomed GmbH Ciclésonide amorphe
US20090075959A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched ciclesonide
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (fr) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
MX2010009303A (es) * 2008-03-13 2010-12-02 Farmabios Spa Proceso para la preparacion de derivados de pregnano.
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
AU2009247021B2 (en) * 2008-05-13 2012-06-07 Astrazeneca Ab Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
WO2009138707A1 (fr) 2008-05-13 2009-11-19 Astrazeneca Ab Dérivés de quinuclidine utilisés comme antagonistes des récepteurs muscariniques m3
RU2509077C2 (ru) 2008-05-27 2014-03-10 Астразенека Аб Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
US20100120737A1 (en) * 2008-11-10 2010-05-13 Martin Feth Amorphous ciclesonide
WO2010067102A1 (fr) 2008-12-09 2010-06-17 Astrazeneca Ab Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
ES2471145T3 (es) 2009-03-09 2014-06-25 Mikasa Seiyaku Co,. Ltd. Compuesto esteroide
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
MY171317A (en) 2009-10-01 2019-10-08 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011079232A1 (fr) * 2009-12-23 2011-06-30 Psivida Us, Inc. Dispositifs d'administration à libération prolongée
WO2011093814A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Compositions pharmaceutiques combinées comprenant du formotérol et du ciclésonide
WO2011136752A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Composition pharmaceutique combinée comprenant du carmotérol et du ciclésonide pour le traitement de maladies respiratoires
CN102477064B (zh) * 2010-11-23 2014-06-11 天津金耀集团有限公司 一种制备环索奈德的16,17缩酮中间体
EP2744479A1 (fr) 2011-08-18 2014-06-25 Takeda GmbH Produit aérosol pharmaceutique pour l'administration par inhalation orale ou nasale
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
WO2013109212A1 (fr) 2012-01-16 2013-07-25 Mahmut Bilgic Formulations en poudre sèche comprenant de la ciclésonide
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
WO2014007772A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation contenant du glucose anhydre
WO2014007770A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
WO2014007781A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
WO2014007771A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un antagoniste du récepteur muscarinique
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
WO2016120891A1 (fr) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Nouveau procédé de préparation de stéroïdes de type glucocorticoïde
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN106749493A (zh) * 2017-01-09 2017-05-31 河南利华制药有限公司 一种哈西奈德中间体的制备工艺
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2024020164A2 (fr) * 2022-07-21 2024-01-25 Firefly Bio, Inc. Agonistes du récepteur des glucocorticoïdes et leurs conjugués

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3079384A (en) * 1960-10-10 1963-02-26 Olin Mathieson C-ring substituted 6alpha-halo steroids and process for producing them
SE378109B (fr) * 1972-05-19 1975-08-18 Bofors Ab
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378110B (fr) * 1972-05-19 1975-08-18 Bofors Ab
CH608244A5 (en) * 1974-02-27 1978-12-29 Pierrel Spa Process for the preparation of steroids
US4272446A (en) * 1974-02-27 1981-06-09 Pierrel S.P.A. Steroids and process for preparing the same
GB1504294A (en) * 1974-03-05 1978-03-15 Palladino G 6 beta-fluoropregnane compounds
NL7412537A (nl) * 1974-05-17 1975-11-19 Lark Spa Werkwijze voor het bereiden van 16.17-cyclische acetalen en ketalen van 9-(alpha)-halogeensteroiden.
US4036831A (en) * 1975-10-28 1977-07-19 Steroid Development Company Establishment Trimethyl siloxane steroid intermediates
DE3012888A1 (de) * 1980-03-31 1981-10-08 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neue steroide und verfahren zu ihrer herstellung
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
DE3640709A1 (de) * 1986-11-28 1988-06-09 Schering Ag Verfahren zur herstellung von 6(alpha),9(alpha)-difluor-11ss,17(alpha)-dihydroxy-16(alpha)-methyl-4-pregnen-3,20-dion und dessen derivate

Also Published As

Publication number Publication date
FR2666585B1 (fr) 1994-09-09
KR920006365A (ko) 1992-04-27
HK1005881A1 (en) 1999-01-29
PT98897B (pt) 2000-10-31
NL194917C (nl) 2003-09-01
AT402930B (de) 1997-09-25
NL300196I1 (nl) 2005-08-01
GB9118967D0 (en) 1991-10-23
ES2034893A1 (es) 1993-04-01
ATA176991A (de) 1997-02-15
GB2247680A (en) 1992-03-11
DE4129535A1 (de) 1992-03-12
JPH04257599A (ja) 1992-09-11
GR1001529B (el) 1994-03-31
NL9101472A (nl) 1992-04-01
NL300196I2 (nl) 2005-10-03
DE122005000030I2 (de) 2007-12-06
KR100193085B1 (ko) 1999-06-15
FR2666585A1 (fr) 1992-03-13
BE1005876A5 (nl) 1994-02-22
JP3292928B2 (ja) 2002-06-17
CA2050812A1 (fr) 1992-03-08
GR910100353A (en) 1992-09-11
CH683343A5 (de) 1994-02-28
LU88001A1 (fr) 1992-06-01
US5482934A (en) 1996-01-09
DE4129535C2 (de) 2001-03-15
CA2050812C (fr) 2003-07-29
AU649472B2 (en) 1994-05-26
DE122005000030I1 (de) 2005-10-06
IT1251376B (it) 1995-05-09
ES2034893B1 (es) 1994-01-01
ITMI912296A0 (it) 1991-08-28
BR1100860A (pt) 1999-08-31
PT98897A (pt) 1992-07-31
ITMI912296A1 (it) 1993-02-28
AU8368691A (en) 1992-03-12
GB2247680B (en) 1994-06-01

Similar Documents

Publication Publication Date Title
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU88736I2 (fr) Cefquinome et ses dérivés pharmaceutiquement acceptables (COBACTAN)
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
LU91189I2 (fr) Atazanavir sulphate et ses dérivés pharmaceutiquement acceptables (REYATAZ)
LU90037I2 (fr) Konakion et ses dérivés pharmaceutiquement acceptables
LU91197I2 (fr) Azoxystrobin et folpel et leurs dérivés pharmaceutiquement acceptables (QUADRIS MAX).
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
LU91163I2 (fr) Hydrobromure de darifénacine et ses dérivés pharmaceutiquement acceptables (EMSELEX.
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
LU91655I2 (fr) Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®)
BR9101311A (pt) Fralda
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
NL194821B (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FI932809A0 (fi) Kaernreaktoranlaeggning med en kaernspaerranordning och foerfarande foer avkylning av densamma i naturligt kretslopp
DE69119329T2 (de) Actinonin-Derivate
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
DK0535034T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
ATE144765T1 (de) Hiv-hemmende benzenacetamidderivate
LU88843I2 (fr) Ropivacaine et ses dérivés pharmaceutiquement acceptables (Naropine R)
OA09840A (fr) dérivés de pipéridine, leur préparation et leur application en thérapeutique
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables